The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis.

Abstract

OBJECTIVE:

To determine whether the presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies at presentation is of prognostic value in patients with palindromic arthritis.

METHODS:

Stored sera, taken around the time of presentation from patients with palindromic arthritis, where available, were assessed for anti-CCP antibodies, and results were correlated with subsequent clinical outcome.

RESULTS:

Twenty-nine of 61 patients had progressed to rheumatoid arthritis after a mean followup of 5.4 years; 83% of these had had anti-CCP antibodies in their baseline sera.

CONCLUSION:

The sensitivity/specificity and likelihood ratios for CCP antibodies were better than rheumatoid factor in predicting outcome.

• Authors: Anthony S Russell, Al Devani, Walter P Maksymowych
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 33 Issue 7 Pg. 1240-2 (Jul 2006) ISSN: 0315-162X [Print] Canada
• PMID: 16724377 (Publication Type: Journal Article)

Chemical References

• Antibodies, Antinuclear
• Biomarkers
• Peptides, Cyclic
• cyclic citrullinated peptide

Topics

• Antibodies, Antinuclear (blood)
• Arthritis, Rheumatoid (diagnosis, immunology)
• Biomarkers (blood)
• Disease Progression
• Early Diagnosis
• Fluorescent Antibody Technique
• Humans
• Peptides, Cyclic (blood, immunology)
• Predictive Value of Tests
• Rheumatology (methods)